Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) EBT (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed EBT for 15 consecutive years, with -$3.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT fell 62.18% year-over-year to -$3.7 million, compared with a TTM value of -$14.5 million through Sep 2025, down 20.08%, and an annual FY2024 reading of -$11.6 million, up 24.08% over the prior year.
  • EBT was -$3.7 million for Q3 2025 at BioRestorative Therapies, down from -$3.3 million in the prior quarter.
  • Across five years, EBT topped out at -$2.3 million in Q3 2024 and bottomed at -$15.1 million in Q1 2021.
  • Average EBT over 5 years is -$4.4 million, with a median of -$3.7 million recorded in 2025.
  • The sharpest move saw EBT tumbled 1738.2% in 2021, then soared 66.43% in 2022.
  • Year by year, EBT stood at -$4.0 million in 2021, then decreased by 16.78% to -$4.7 million in 2022, then skyrocketed by 31.21% to -$3.2 million in 2023, then increased by 16.47% to -$2.7 million in 2024, then tumbled by 37.87% to -$3.7 million in 2025.
  • Business Quant data shows EBT for BRTX at -$3.7 million in Q3 2025, -$3.3 million in Q2 2025, and -$4.8 million in Q1 2025.